Investigators applied CAR T cells at five dose levels (1 × 105 to 1 × 108 CAR/kg cells) to 10 patients with colorectal cancer to demonstrate the safety and efficacy of treatment with CEA CAR T cells. The gene discussed is CEACAM5; the disease is colorectal cancer.